Der er udført 2 kliniske forsøg med patienter, der er resistente eller intolerante over for imatinib; det primære effekt- endpoint i disse forsøg var McyR (Major Cytogenetic Response):
Two clinical trials were conducted in patients resistant or intolerant to imatinib; the primary efficacy endpoint in these trials was Major Cytogenetic Response (MCyR).